Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Fuse Science Round II Research Offers Major Advancements in Delivery of Active Pharmaceutical Ingredients

June 4, 2013

MIAMI LAKES, Fla., June 4, 2013 /PRNewswire/ — Fuse Science, Inc. (OTCQB: DROP), (www.fusescience.com) a consumer products and delivery technology company that is developing new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals is pleased to announce their Round II Research results have shown their proprietary delivery technology has successfully delivered therapeutic doses of varying-size compounds directly through the epidermis.

During the Company’s Round I Research conducted in 2012, caffeine was delivered effectively through the epidermis. This initial study provided four basic principles surrounding Fuse Science’s proprietary technology: speed, variability, duration and functionality.

The Round II Research results released May 31, 2013 expanded the prior proof of concepts by showing Fuse’s proprietary delivery technology successfully delivering numerous Active Pharmaceutical Ingredients (“API’s”) of varying size, rigidity and lipophilicity, whether it is fat or water soluble, directly through the epidermis. Nine Fuse Science formulations were tested in an ex vivo penetration study through human epidermis. Eight compounds were tested with the proprietary encapsulation technology and one of them was tested with a second proprietary encapsulation formulation. Fuse Science’s proprietary technology delivered Insulin, Paclitaxel, Estradiol, Nicotinic Acid, Folic Acid, Polyethylene Glycol (PEG), Vitamin E Acetate and caffeine with 100% success rate.

Jeanne Hebert, Vice President of Market and Clinical Research of Fuse Science stated, “We are very excited with the recent findings that are providing clear evidence that our delivery technology could be a significant advancement in how medicines, vitamins and nutritional compounds are delivered and absorbed into the human body.”

Insulin, one of the compounds previously analyzed, is a reliable proof of principle for the technology. Because it is such a large molecule, and a protein, it has been traditionally very difficult to deliver through the skin unless it was given via an injection. During this study, it passed through even at low concentrations in the Company’s proprietary formulation.

In addition, two other large-market drugs Estradiol, used to treat the symptoms of menopause and Paclitaxel, a prescription cancer drug, were tested. It is Fuse’s hypothesis, based on the success of their research, that they will be successful in the delivery of therapeutic doses of each, within their matrix, in a simple roll-on application.

The primary benefits that may develop from these studies are:

  • Enhanced delivery option for complex API’s
  • Improved bio-availability or enhanced absorption in the body
  • Stronger product efficacy
  • Enhanced ease of use (A simple roll-on application)
  • Expansion of therapeutic options for acute, rapid onset conditions

Data from these preliminary research studies show that with little requirement for optimization, the technology can provide for the transdermal delivery of drugs at clinically relevant doses for the treatment of a wide variety of ailments and diseases. Most compounds showed improvement of delivery over each time-point during the course of the study. The lack of plateaus would suggest that delivery improves with time and can be sustained for periods much greater than twenty-four hours.

This latest research is particularly relevant to the active licensing and M&A efforts of the company.

The full Round II Research report can be found by visiting the “Clinical Research” section of the Fuse Science Investor Relations page here: http://ir.stockpr.com/fusescience/clinical-research.

About Fuse Science, Inc.

Fuse Science, Inc. (OTCQB: DROP), is an innovative consumer products and delivery technology company based in Miami Lakes, Florida. Fuse Science holds the rights to new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals. The Company maintains the rights to sublingual and transdermal delivery systems for bioactive agents that can now, for the first time, effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can bypass the gastrointestinal tract and enter the blood stream directly – all in a concentrated “DROP” form that is simply applied under the tongue. The Fuse Science technology is designed to accelerate conveyance of medicines or nutrients relative to traditional pills and liquids and can enhance how consumers receive these products. Information about Fuse Science is available online at www.fusescience.com and www.poweredbyfuse.com or by calling 305-503-FUSE (3873).

For Fuse news as it happens, follow @Fuse_Science on Twitter and Like Us on Facebook!

Get all Fuse Science corporate updates sent directly to you; sign up for Fuse News Alerts HERE.

    For more information:          To schedule an interview:

    Fuse Science, Inc.             Gus DeQuesada

    Investor Relations             Michelsen Advertising

    Direct: (305) 503-3873, Ext. 2 C-305-733-1410 / 786-488-7138

    Email: ir@fusescience.com      prnews@michelsenadvertising.com

SOURCE Fuse Science, Inc.


Source: PR Newswire